BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34012003)

  • 1. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
    Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
    ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and
    Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
    ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
    Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
    Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
    Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
    Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
    Ford BM; Franks LN; Radominska-Pandya A; Prather PL
    PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
    Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays.
    Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V
    Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.